Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy

American Heart Journal

Volumn 146, Issue 6, 2003, Pages 1112-1114

  Chang, Su Min ^a   Sekandarzad, Mir Wais ^a   Jiang, Sharon ^a   Nagueh, Sherif ^a   Spencer III, William ^a   Lakkis, Nasser ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SM 677 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CREATINE KINASE;

ADULT; ARTICLE; BOLUS INJECTION; ECHOCARDIOGRAPHY; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE OUTFLOW TRACT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NONSURGICAL INVASIVE THERAPY; NONSURGICAL SEPTAL REDUCTION THERAPY; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 0344196944     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00504-0     Document Type: Article

References (12)

1. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
2. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophy cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis 1985;28:1-83.
3. Sigwart U. Nonsurgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1996;346:211-4.
4. Knight C, Kurbaan A, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1997;95:2075-81.
5. Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute result and 3 month follow up in 25 patients. J Am Coll Cardiol 1998;252-8.
6. Lakkis N, Nagueh S, Kleiman N, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-5.
7. Lakkis N, Nagueh S, Killip D, et al. Nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor Experience (1996-1999). J Intervent Cardiol 2000;13:157-9.
8. Lakkis N, Nagueh S, Dunn K, et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one year follow up. J Am Coll Cardiol 2000;36:852-5.
9. Boekstegers P, Steinbigler P, Molnar A, et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:846-53.
10. Faber L, Meissner A, Ziemssen P, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000;83:326-31.
11. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1492-6.
12. Knight C. Five years of percutaneous transluminal septal myocardial ablation. Heart 2000;83:255-6.